New combo therapy for tough prostate cancer shows promise in early trial

NCT ID NCT03869762

First seen Apr 23, 2026 · Last updated Apr 30, 2026 · Updated 1 time

Summary

This study tested a combination of two drugs, denosumab and enzalutamide, in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than historical results with enzalutamide alone. Only 7 men enrolled before the study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Adelaide and Meath incorporating National Children's Hopsital

    Dublin, Leinster, Ireland

  • Cork University Hospital

    Cork, Munster, Ireland

  • Galway University Hospital

    Galway, Connacht, Ireland

  • Sligo University Hospital

    Sligo, Connacht, Ireland

  • St. Vincent's Hospital

    Dublin, Leinster, Ireland

  • University Hospital Limerick

    Limerick, Munster, Ireland

  • University Hospital Waterford

    Waterford, Munster, Ireland

Conditions

Explore the condition pages connected to this study.